Fuel your
next discovery

The road to faster, more efficient and ethical biological testing starts with Nagi Bioscience

Are traditional biological testing models limiting your team’s potential? Then it’s time to try another way.

SydLab One system high throughput in vivo testing

Unlock the potential of Organism-On-Chip testing for your research

SydLab™ is the first, fully-automated, high-content screening platform of drugs and chemicals using C. elegans nematodes.

  • Early, relevant, full-organism testing
  • Unprecedented volume and scale
  • Accessible to any lab

The data to do more

Fundamental Research

Unlock data and insights that keep your team at the forefront of progress.

Candidate Discovery

Make data-driven decisions to fast-track the most promising compounds.

Safety Toxicology

De-risk product development and advance to clinical studies with confidence.


End-to-end solutions that work in any lab. Including yours.

A partner, not just a supplier, our contract laboratory solutions are designed to make sure your team gets the answers and insights they need to drive new developments forward.

Erez Aminov

We are very pleased with Nagi Bioscience. Their innovative technology has been instrumental in allowing us to gather critical scientific data quickly, providing invaluable insights that significantly advance our research in longevity.

Erez Aminov

CEO, Telomir Pharmaceuticals, Inc.

Prof. Konstantinos Palikaras, PhD

By improving precision and enhancing reproducibility, SydLab™ One empower us to explore new frontiers in critical fields of medical science. We are excited to leverage this fully automated, end-to-end solution in our projects.

Prof. Konstantinos Palikaras, PhD

Group Leader of the Unit of Neurogenetics and Ageing, Laboratory of Physiology, University of Athens (NKUA)

Irina Fingerhut

Their high-throughput approach provided clear, quantifiable insights into the lifespan and functional effects of our lead combinations— critical data that helped de-risk and prioritize our therapeutic strategy.

Irina Fingerhut

Co-Founder/Sole Director, ElixIRA Pharma AG

Latest News & Publications

How C. elegans data supports early biotech R&D

Discover 3 ways C. elegans models accelerate early-stage biotech R&D—from high-throughput screening…

The 1mm Powerhouse: C. elegans in Aging Research

What if one of the most powerful tools in the fight against…

NAMs, Automation and AI Symposium at SETAC 2025

Register to our lunch symposium about novel alternative model organisms as part…